13.63
price up icon2.10%   0.28
 
loading
Upstream Bio Inc stock is traded at $13.63, with a volume of 399.32K. It is up +2.10% in the last 24 hours and up +25.16% over the past month. Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$13.35
Open:
$13.52
24h Volume:
399.32K
Relative Volume:
0.98
Market Cap:
$733.21M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-10.61
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
+27.15%
1M Performance:
+25.16%
6M Performance:
+31.18%
1Y Performance:
+0.00%
1-Day Range:
Value
$12.74
$13.96
1-Week Range:
Value
$10.54
$13.96
52-Week Range:
Value
$5.14
$29.46

Upstream Bio Inc Stock (UPB) Company Profile

Name
Name
Upstream Bio Inc
Name
Phone
781-208-2466
Name
Address
890 WINTER STREET, SUITE 200, WALTHAM
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
UPB's Discussions on Twitter

Compare UPB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
UPB
Upstream Bio Inc
13.63 718.15M 2.22M -40.51M -46.53M -1.2847
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Upstream Bio Inc Stock (UPB) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-05-24 Initiated JP Morgan Overweight
Nov-05-24 Initiated Piper Sandler Overweight
Nov-05-24 Initiated TD Cowen Buy
Nov-05-24 Initiated William Blair Outperform

Upstream Bio Inc Stock (UPB) Latest News

pulisher
Jul 25, 2025

Upstream Bio Inc (UPB) Stock: A Year of Highs and Lows - investchronicle.com

Jul 25, 2025
pulisher
Jul 23, 2025

What drives Upstream Bio Inc. stock priceOutstanding trading profits - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Upstream Bio Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Upstream Bio Inc. stockOutstanding capital returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Upstream Bio Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

J.P. Morgan Maintains UpStream Bio(UPB.US) With Buy Rating - 富途牛牛

Jul 19, 2025
pulisher
Jul 18, 2025

how upstream bio inc. stock performs during market volatilityFree Stock Market Insider Analysis - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest

Jul 18, 2025
pulisher
Jul 17, 2025

What risks could impact Upstream Bio Inc. stock performanceHigh Potential Shares - Newser

Jul 17, 2025
pulisher
Jul 15, 2025

Why Upstream Bio Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Upstream Bio Inc. stock performs during market volatilityFast Gains With Reduced Risk - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Upstream Bio management to meet with Piper Sandler - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Upstream Bio Inc. stock price move sharplyFree VIP Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Will Q3 Shape Up To Be A VIBRANT Quarter For Upstream Bio? - RTTNews

Jul 09, 2025
pulisher
Jul 08, 2025

Upstream Bio doses first patient in Phase 2 trial of verekitug in COPD - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio announces first patient dosed in phase 2 clinical trial of Verekitug - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio begins phase 2 COPD trial for verekitug - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Upstream Bio Announces First Patient Dosed in Phase 2 - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough COPD Drug Trial Launches with Unique 24-Week Dosing Schedule, Targeting 670 Patients - Stock Titan

Jul 08, 2025
pulisher
Jun 30, 2025

Upstream Bio, Inc.(NasdaqGS: UPB) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

Rhumbline Advisers Has $82,000 Stock Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 27, 2025
pulisher
Jun 19, 2025

Upstream Bio Plunges 11.54% Amid Clinical Trial Data Anticipation - AInvest

Jun 19, 2025
pulisher
Jun 16, 2025

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks

Jun 16, 2025
pulisher
Jun 15, 2025

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable

Jun 15, 2025
pulisher
Jun 15, 2025

Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - The Manila Times

Jun 15, 2025
pulisher
Jun 15, 2025

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq

Jun 15, 2025
pulisher
Jun 15, 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 15, 2025
pulisher
Jun 12, 2025

Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail

Jun 11, 2025
pulisher
Jun 08, 2025

Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Upstream Bio to Present Mechanistic Insights into - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

Jun 04, 2025

Upstream Bio Inc Stock (UPB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Upstream Bio Inc Stock (UPB) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
ORBIMED ADVISORS LLC
Director
Oct 15 '24
Buy
17.00
825,000
14,025,000
4,554,873
AI Upstream LLC
10% Owner
Oct 15 '24
Buy
17.00
1,175,000
19,975,000
1,175,000
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):